Objective: The main objective of this research is to formulate, optimize, and evaluate raft-forming chewable tablets of Nizatidine. Various raft-forming agents were used in preliminary screening. Sodium alginate showed maximum raft strength, so tablets were prepared using sodium alginate as the raft forming agent, along with calcium carbonate (CaCO) as antacid and raft strengthening agent, and sodium bicarbonate (NaHCO) as a gas generating agent.
Research Design And Methods: Raft forming chewable tablets containing Nizatidine were prepared by direct compression and wet granulation methods, and evaluated for drug content, acid neutralization capacity, raft strength, and in-vitro drug release in 0.1 N HCl. Box-Behnken design was used for optimization.
Results: Two optimized formulations were predicted from the design space. The first optimized recommended concentrations of the independent variables were predicted to be X = 275.92 mg, X = 28.60 mg, and X = 202.14 mg for direct compression technique and the second optimized recommended concentrations were predicted to be X = 253.62 mg, X = 24.60 mg, and X = 201.77 mg for wet granulation technique. Optimized formulations were stable at accelerated environmental testing for six months at 35 °C and 45 °C with 75% relative humidity. X-Ray showed that the raft floated immediately after ingestion and remained intact for ∼3 h.
Conclusion: Raft was successfully formed and optimized. Upon chewing tablets, a raft is formed on stomach content. That results in rapid relief of acid burning symptoms and delivering the drug into systemic circulation with enhanced bioavailability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/03639045.2019.1569033 | DOI Listing |
J Vet Intern Med
January 2025
Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, Germany.
Background: Myxomatous mitral valve disease (MMVD) is frequently diagnosed in small breed dogs. Pimobendan oral solution has been developed to improve dosing accuracy in small and toy breed dogs.
Hypothesis/objectives: Demonstrate bioequivalence of pimobendan oral solution with pimobendan chewable tablets using a pharmacokinetic and a pharmacodynamic study in healthy purpose bred dogs.
Nutrients
December 2024
Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok 65000, Thailand.
Background/objectives: UV radiation is a primary cause of skin damage and photoaging. β-carotene, a potent antioxidant, aids in mitigating UV-induced oxidative stress and enhancing skin photoprotection. This research aimed to evaluate the efficacy of a nutraceutical product designed to prevent photoaging.
View Article and Find Full Text PDFLife (Basel)
December 2024
Physiopathology Department, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology, 540142 Targu Mures, Romania.
Background: This systematic review aimed to synthesize the existing evidence on the use of () probiotics as prophylactic or therapeutic tools for pediatric oral, dental, and respiratory diseases.
Methods: A comprehensive search was carried out across multiple databases using the following terms: , probiotic, children, pediatric.
Results: The systematic literature search identified 613 publications, which were meticulously screened, and, ultimately, 15 suitable citations were included in this systematic review.
Clin Ther
January 2025
Unicycive Therapeutics, Inc., Los Altos, CA.
Purpose: Phosphate binders (PB) are integral to hyperphosphatemia management in patients with end-stage kidney disease. PB efficacy is adversely affected by nonadherence and limited phosphate-binding capacity relative to dietary intake. Oxylanthanum carbonate is an investigational novel nanotechnology product that combines lanthanum, which has the highest binding capacity of available PBs, with a smaller pill size that is swallowed with water rather than chewed.
View Article and Find Full Text PDFPharmaceuticals (Basel)
November 2024
Department of Pharmaceutical Engineering, Cheongju University, Cheongju 28503, Republic of Korea.
Famotidine is a histamine H2 receptor antagonist used in the treatment of gastrointestinal disorders. It is available in multiple formulations, including film-coated tablets, chewable tablets, oral suspension, and injections. The purpose of this study was to develop and evaluate the film-coated tablet (FT) containing famotidine, magnesium hydroxide, and precipitated calcium carbonate, designed to be pharmaceutically equivalent to the marketed chewable tablet (CT).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!